glp-1/gip dual agonist weight loss Why does GLPโ1 combined with GIP and/or GCG agonist have greater effect than GLPโ1 agonist alone in obese adults without type 2 diabetes? - Jiang - 2025 ๐งฌ The Future of Weight
Description
Decreasing glucagon release
Over half (56%) of GLP-1 users say they started making healthier food choices during treatment
These results established tirzepatide as the most potent agent in the current pharmacologic armamentarium for obesity
Both drugs contain semaglutide, with Ozempic containing a smaller amount of the agent
Sterne JAC, Savovi J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials
PLoS ONE (2014) 9:e87488
